Overview

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Status:
Recruiting

Trial end date:
2023-07-15

Target enrollment:

Participant gender:

Summary

This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)
Northwestern University

Collaborators:

BHR Pharma, LLC
National Cancer Institute (NCI)

Treatments:

Afimoxifene
Citric Acid
Tamoxifen